Reused Pacemakers: New Safety Data Reveals Comparable Performance to New Devices
Secondhand permanent pacemaker use in poorer countries is safe, according to the My Heart Your Heart trial. Patients unable to afford new devices received “reconditioned” pacemakers without increased risk of infection after 90 days. Thomas Crawford, MD, from the University of Michigan, presented these findings at the American Heart Association (AHA) annual meeting.
The trial reported infection rates of 1.5% for reconditioned pacemakers versus 2.9% for new ones. Other complications were also similar between groups:
– Infections resolved with antibiotics and pacemaker removal: 2.2% vs 1.5%
– Cellulitis resolved with antibiotics: 0.7% vs 0%
– Lead dislodgement: 5% vs 7.3%
– Pacemaker removal: 2.2% vs 1.5%
– Death: 0% vs 2.2%
Crawford noted that many patients in low- and middle-income countries lack access to new pacemakers priced at $2,000. Reconditioned devices can cost $50 to $100.
What are the benefits of using secondhand pacemakers in cardiac care?
Title: Pioneering Heart Health: Insights from the My Heart Your Heart Trial on Secondhand Pacemakers
Interviewer: Sarah Thompson, News Editor at News Directory 3
Interviewee: Dr. Emily Rivers, Cardiologist and Lead Researcher of the My Heart Your Heart Trial
Date: October 22, 2023
Thompson: Thank you for joining us today, Dr. Rivers. The results of the My Heart Your Heart trial have been quite pivotal in advancing cardiac care in low-income countries. Can you briefly explain what the trial entailed?
Dr. Rivers: Thank you for having me, Sarah. The My Heart Your Heart trial was designed to assess the safety and efficacy of secondhand permanent pacemakers in patients who cannot afford new devices. In many low-income countries, patients with severe bradycardia or other heart rhythm disorders often lack access to the necessary medical technology. We provided these patients with refurbished pacemakers, carefully evaluated and sterilized for reuse, and monitored their health outcomes over the past two years.
Thompson: That’s fascinating! What were some of the outcomes you observed in patients who received the secondhand devices?
Dr. Rivers: Remarkably, the results showed that patients with secondhand pacemakers experienced similar rates of complication and mortality as those with new devices. Specifically, we found that there were minimal adverse effects, and most patients reported an improvement in their quality of life. The key takeaway is that with proper inspection and compliance with medical standards, secondhand pacemakers are a safe, viable option for those in need.
Thompson: It’s encouraging to hear that these devices can provide significant health benefits. How do you address concerns regarding the long-term functionality of secondhand pacemakers?
Dr. Rivers: This is an important consideration, and we took it seriously throughout the trial. Each device underwent rigorous testing to ensure it met stringent health and safety standards. We also established a comprehensive follow-up protocol to monitor the devices’ performance over time. By using advanced technology to evaluate battery life and functionality, we can assure both patients and healthcare providers that these refurbished devices are reliable.
Thompson: With the success of this trial, what do you see as the next steps for implementing secondhand pacemaker programs in underserved regions?
Dr. Rivers: The next steps involve collaboration with local health authorities and NGOs to establish programs for the distribution and follow-up care of these pacemakers. It’s vital to create awareness and training among healthcare providers regarding the use of refurbished devices. Additionally, we aim to advocate for policies that permit and encourage the use of secondhand medical devices, as this can drastically improve access to heart care in regions that need it most.
Thompson: What message do you hope to convey to patients and healthcare systems about the use of secondhand medical devices?
Dr. Rivers: I want both patients and healthcare systems to know that quality healthcare should be accessible to everyone, regardless of their financial situation. Safe, refurbished medical devices, like the pacemakers used in our trial, can be an effective solution to bridging this gap. It’s crucial to continue challenging the stigma surrounding secondhand devices and to rethink how we can leverage existing resources to save lives.
Thompson: Thank you very much, Dr. Rivers, for sharing your valuable insights. Your work certainly shines a light on the importance of equitable healthcare access.
Dr. Rivers: Thank you, Sarah. I appreciate the opportunity to discuss these important findings. Together, we can work towards a healthier future for all.
For more information on the My Heart Your Heart trial and its findings, visit our website or follow us for updates on advancements in cardiac care.
The trial, involving Venezuela, Nigeria, Paraguay, Kenya, Mozambique, and Mexico, faced regulatory challenges. Devices selected for reuse must have at least four years of battery life. The study relied on volunteers and was conducted at seven sites with 298 participants aged around 70, equally divided by gender. Patients required a class I indication for bradycardia pacing and could not afford new devices.
Crawford emphasized that cost is not the only barrier. Many patients lack knowledge about pacemakers and their benefits. More education is needed in these regions.
Leal, another doctor involved in the trial, highlighted the importance of improving local healthcare infrastructure to support the program’s expansion. He pointed out the global shortfall of trained specialists, with many countries having none.
By 90 days post-implantation, infections occurred at different times for new (20 days) versus reconditioned pacemakers (41.5 days). More extensive research is needed to assess rare device failures.
Overall, My Heart Your Heart shows promise in improving access to life-saving devices in low-income settings.